Market Cap: 65.3598B; Large Cap
P/E Ratio: 15.22; Fwd: 13.89
EPS (TTM): $40.96
Div. Yield: 0.58%

RE

REGNNASDAQ— Regeneron Pharmaceuticals Inc Price & Analysis

Regeneron Pharmaceuticals Inc

HEALTHCARE — BIOTECHNOLOGY

$632.90

+$12.76+2.06%

Market Cap: 65.3598B; Large Cap
P/E Ratio: 15.22; Fwd: 13.89
EPS (TTM): $40.96
Div. Yield: 0.58%

Technical Summary

RSI (14)50.41Neutral

SMA (50)$666.23Bearish

SMA (200)$696.97Bearish

MACD-11.1245Bullish

Bollinger$597.04 – $633.84Mid

Stochastic67.79Neutral

Theo Outlook

Regeneron Pharmaceuticals (REGN) presents a bullish thesis with a trailing P/E of 15.46, market capitalization of $66.35 billion, TTM revenue of $14.92 billion (up 19% YoY), and diluted EPS of $40.95. The forward P/E of 14.1 and PEG ratio of 1.093 suggest the stock is attractively valued relative to its earnings growth trajectory in the biotechnology sector.

Key catalysts include strong quarterly revenue momentum of 19% YoY and a robust pipeline in cytokine and receptor therapies, supported by analyst ratings of 5 Strong Buy and 16 Buy with a consensus target price of $833.31. Recent product expansions in ophthalmology and immunology, alongside institutional ownership at 92.26%, position the company for continued earnings momentum into 2026.

Risks encompass regulatory hurdles in drug approvals, competitive pressures from larger pharma players, and macroeconomic headwinds such as interest rate sensitivity affecting biotech valuations. Mitigations include Regeneron's diversified revenue streams, high return on equity of 14.5%, and a conservative beta of 0.238 that reduces volatility exposure. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Theo Outlook

Regeneron Pharmaceuticals (REGN) presents a bullish thesis with a trailing P/E of 15.46, market capitalization of $66.35 billion, TTM revenue of $14.92 billion (up 19% YoY), and diluted EPS of $40.95. The forward P/E of 14.1 and PEG ratio of 1.093 suggest the stock is attractively valued relative to its earnings growth trajectory in the biotechnology sector.

Key catalysts include strong quarterly revenue momentum of 19% YoY and a robust pipeline in cytokine and receptor therapies, supported by analyst ratings of 5 Strong Buy and 16 Buy with a consensus target price of $833.31. Recent product expansions in ophthalmology and immunology, alongside institutional ownership at 92.26%, position the company for continued earnings momentum into 2026.

Risks encompass regulatory hurdles in drug approvals, competitive pressures from larger pharma players, and macroeconomic headwinds such as interest rate sensitivity affecting biotech valuations. Mitigations include Regeneron's diversified revenue streams, high return on equity of 14.5%, and a conservative beta of 0.238 that reduces volatility exposure. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Company Overview

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

Fundamental Snapshot

Revenue: 14.9196B
EBITDA: 4.3828B
Gross Profit: 6.5475B
Operating Margin: 20.7%
Profit Margin: 29.6%
ROE: 14.5%
Book Value: $308.32
Beta: 0.238
52-Wk High: $818.9
52-Wk Low: $516.07
Avg Volume: 1.2011M
PEG Ratio: 1.085

Frequently Asked Questions

What is Regeneron Pharmaceuticals' business model?

Regeneron Pharmaceuticals operates as a biotechnology company focused on discovering, developing, and commercializing medicines targeting serious diseases through its proprietary VelociSuite technologies. It generates revenue primarily from product sales like Eylea and Dupixent, along with collaboration agreements, with TTM revenue of $14.92 billion.

What are Regeneron's main revenue sources?

The company's primary revenue comes from sales of its key drugs in ophthalmology and immunology, contributing to $14.92 billion TTM revenue. Additional income stems from licensing and collaboration deals, with gross profit margin at 43.9% supporting profitability.

What competitive advantages does REGN have?

Trading Data

Open: $623.64
Previous Close: $620.14
Day Range: $623.44 – $638.76
Volume: 1.2111M
Shares Outstanding: 103.022M
Analyst Target: $833.31

Related Assets

Intuitive Surgical Inc

Vertex Pharmaceuticals Inc

IDEXX Laboratories Inc

$551.50

-0.62%

Get Deeper Analysis

Ask Theo anything about REGN — earnings, valuation, technicals, or portfolio fit.

Try HeyTheo Free

Company Overview

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

Fundamental Snapshot

Revenue: 14.9196B
EBITDA: 4.3828B
Gross Profit: 6.5475B
Operating Margin: 20.7%
Profit Margin: 29.6%
ROE: 14.5%
Book Value: $308.32
Beta: 0.238
52-Wk High: $818.9
52-Wk Low: $516.07
Avg Volume: 1.2011M
PEG Ratio: 1.085

Frequently Asked Questions

What is Regeneron Pharmaceuticals' business model?

Regeneron Pharmaceuticals operates as a biotechnology company focused on discovering, developing, and commercializing medicines targeting serious diseases through its proprietary VelociSuite technologies. It generates revenue primarily from product sales like Eylea and Dupixent, along with collaboration agreements, with TTM revenue of $14.92 billion.

What are Regeneron's main revenue sources?

The company's primary revenue comes from sales of its key drugs in ophthalmology and immunology, contributing to $14.92 billion TTM revenue. Additional income stems from licensing and collaboration deals, with gross profit margin at 43.9% supporting profitability.

What competitive advantages does REGN have?

Regeneron benefits from strong R&D capabilities, a diversified pipeline, and high institutional ownership of 92.26%. Its low beta of 0.238 and solid ROE of 14.5% provide resilience, while a P/E of 15.46 reflects efficient operations compared to peers.

What are the key risks for REGN investors?

Key risks include regulatory approval delays, intense competition in biotech, and potential macro pressures on healthcare spending. The company mitigates these through its $66.35B market cap, diversified products, and analyst target of $833.31, well above current levels near the 50-day MA of $666.72.

What is the growth outlook for REGN?

REGN shows positive growth with 19% YoY quarterly revenue increase and EPS of $40.95, though earnings growth was -7.2% YoY. With a forward P/E of 14.1, dividend yield of 0.58%, and next earnings likely in Q3 2026, analysts project upside to $833.31 target price.